MA-ULTIVUE/ORACLEBIO
22.7.2020 15:19:06 CEST | Business Wire | Press release
Ultivue , Inc. today announced a collaborative partnership with OracleBio to help further insights and advance personalized tumor characterization in translational and clinical oncology research and drug development using multiplex immunofluorescence staining and imaging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200722005492/en/
The deal connects the histopathology image analysis expertise of OracleBio and the tissue staining capabilities of Ultivue, with the goal of providing pharmaceutical companies with an end-to-end workflow for gaining valuable insights from biomarkers in situ .
OracleBio, a contract research organization based in Scotland, is known for its quantitative digital pathology services, delivering high-quality image analysis while leveraging multiple software platforms in supporting clinical and pre-clinical research.
“OracleBio aim to deliver robust quantitative histopathology data deployed within a quality framework, and that analysis can be heavily dependent on the quality of sample preparation and staining,” says Lorcan Sherry, CSO of OracleBio. “Being able to partner with Ultivue means we can be confident in the staining of the tissue we’re quantifying, which ultimately means more precise data.”
The Cambridge, Massachusetts-based Ultivue develops reagents for staining tissues used for multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex technology is designed for fast and comprehensive exploration of biologically-relevant markers in tissue samples.
“We’ve developed reagents that are workflow-agnostic and can plug-and-play in most customers’ existing laboratory infrastructure, so it makes sense to partner with a like-minded imaging and analysis CRO like you have in OracleBio. At the end of the day, our goal is always to offer our customers relevant and meaningful biological insights from their samples, regardless of their preferred hardware or software,” says Jacques Corriveau, President and CEO of Ultivue.
About OracleBio:
OracleBio is a leading contract research organization (CRO) specializing in quantitative digital pathology, providing histopathology image analysis services to support pre-clinical and clinical R&D.
Using both Indica Labs HALO™ and Visiopharm image analysis software platforms, they can deliver accurate and detailed quantification of nuclear, membrane and cytoplasmic markers on a cell-by-cell basis within histology, IHC and ISH tissue sections.
About Ultivue:
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005492/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Goldman Sachs Alternatives Acquires FGI Worldwide12.5.2026 11:00:00 CEST | Press release
Transaction Accelerates FGI’s Growth and Expands Product Offering FGI Worldwide LLC (“FGI” or the “Company”), a leading provider of working capital financing and trade credit insurance solutions, today announced it has been acquired by the Private Equity business within Goldman Sachs Alternatives. Over its 25-year history, FGI has established a strong reputation as a leader and innovator in asset-based lending and risk mitigation, specializing in multi-jurisdictional working capital solutions that support businesses with flexible financing to drive domestic and global expansion. The acquisition enables FGI to accelerate its growth and expand its suite of financing, risk and Insurtech solutions for clients. In conjunction with the transaction, Sami Altaher, Co-Founder and President of FGI, succeeds David DiPiero as Chief Executive Officer, marking the next chapter in the Company’s evolution. “We are grateful to our team, customers, partners and investors who have made this milestone pos
Kept Alive by ECMO Until Heart Transplant: Sahara Romero's Story of Survival and Recovery, with ECMOlife by Eurosets12.5.2026 10:45:00 CEST | Press release
“Now, for the first time in years, I can live without constantly fearing something could go wrong.” That's how Sahara Romero told her story, presented at the EuroELSO Congress in Dublin (6-8 May), dedicated to lifesaving extracorporeal therapies. Hers is a remarkable journey back to life, where clinical expertise and advanced life-support technologies came together to radically change her fate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511305446/en/ Antonio Petralia, CEO of Eurosets; Sahara Romero, patient; dr. Mario Andrés Mercado Díaz, Intensive care specialist at the Clínica Shaio in Bogotá; Estefanía Giraldo Bejarano, specialist ECMO nurse at the Clínica Shaio in Bogotá Sahara has lived with a serious heart condition since early adolescence. The first signs of heart failure appeared when she was eleven. “When I was doing simple activities, like gymnastics lessons, I got very tired and experienced pain in my chest
New Research From Infobip Finds Disconnected Data and Systems Prevent Brands From Automating Customer Journeys at Scale12.5.2026 10:39:00 CEST | Press release
Global AI-first cloud communications platform Infobip’s 2026 Customer Experience (CX) Maturity Report reveals a widening gap between communications infrastructure investment and CX performance. With ever-increasing customer expectations, achieving CX maturity is the goal for major global brands. This hinges on how well brands can build experiences on mobile channels. There is a fundamental difference between a simple fraud alert on SMS and a two-way WhatsApp chat that allows customers to act immediately. While 96% of brands automate customer interactions in some way, few are delivering a seamless experience. Only 58% of brands say their channels are fully in sync, and 60% have centralized storage of customer data. But looking closer, only 27% use an orchestration platform, and 50% of brands say their tools are fully API-ready. This means half of brands struggle with connecting tools and data and many don't use a unified platform to build truly seamless experiences. This fragmentation i
Rerouting Alone Could Cost Airlines $8 Billion This Summer, New i6 Group Data Shows12.5.2026 10:00:00 CEST | Press release
Operational data from nearly 300 airports reveals that structural fuel costs are cutting into peak-season profits. Plus, European airports increased fuel stock by 62%, ahead of further supply disruption. Airlines flying European long-haul routes are facing a fuel cost penalty that could exceed $8 billion between May and August 2026, according to a new operational data report released today by i6 Group, a global leader in integrated aviation fuel management technology. The report, “Middle East Conflict: Summer 2026 Outlook,” draws on real fueling transactions captured at nearly 300 airports worldwide by i6's Fusion6 platform and provides insight into the costs of the conflict so far and how it might impact summer travel, based on actual fuel supply and into-plane uplift data. Key Findings $5.6 billion – $8.4 billion: Projected industry-wide rerouting fuel cost, May–August 2026 62.2%: Increase in European airport fuel book stocks (April 2026 vs. April 2025) 415,373 tons: Additional CO2 g
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 09:01:00 CEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom